Natural product-based therapy for Deafness: A therapeutic mix encompassing Safranal, Cholecalciferol and DIM (SCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, and improves hearing loss via up regulation of its target genes, 17/November/2017, 5.41 am
What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Deafness: A therapeutic mix encompassing Safranal, Cholecalciferol and DIM (SCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, and improves hearing loss via up regulation of its target genes [easy_payment currency=”USD”] From Significance […]
Natural product-derived therapy for anxiety and depression: Sedanolide, isolated from Celery/Apium graveolens Var. dulce, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 16/November/2017, 11.47 am
Introduction: What they say: A study from Department of Molecular Biology, Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA; Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA; and Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA shows that “Phf8 loss […]
Molecular therapy for Diabetic nephropathy (DN): Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetes Nephropathy, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 16/November/2017, 10.35 am
Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.” This research paper was published, in the 24 April 2017 issue of the journal “Nature Medicine” [One of the best research journals in “Molecular […]
Lifespan extension therapy: 15-deoxy-Delta,12,14-prostaglandin J2 (15d-PGJ2) may increase life span via up-regulation of its target gene BubR1, 16/November/2017, 10.10 am
What they say: Introduction: A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the […]
Molecular therapy for glucose homeostasis and TIIDM: Butylphthalide (3-n-butylphthalide or NBP), found in celery oil, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/November/2017, 5.59 am
Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that “PAX6 maintains ß cell identity by repressing genes of alternative islet cell types.” This research paper was published, in the 12 December 2016 issue of […]
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetic Neuropathy, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 16/November/2017, 5.43 am
Significance of the study: Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost […]